AmnioLife Corporation, a Gainesville, Fla.-based human cells, tissues, and cellular and tissue-based products developer, raised $833k in Series A round of funding.
The round was led by Fountainhead Investment Partners, a healthcare angel investment fund, which is working closely with AmnioLife to structure strategic partnerships with medical device companies.
The company is using the proceeds to support its core manufacturing operations at its Gainesville, FL facility.
Led by Chris Broderick, CEO, AmnioLife is a research and development organization focused on placental-derived technologies. It aims to to commercialize a suite of minimally manipulated tissue products, establish global sales channel partners, and develop a strong IP-position for advanced biologic products. It participated in an IRB-approved study in 2014 that allowed it to validate collection methods of human placental tissue and amniotic fluid, and is working toward vertical integration of its supply chain.